Table 1 Characteristics of clinical trials and patients included in the meta-analysis
From: Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
Trial name | Design | Total enrollment number | Intervention | Control | Study quality |
|---|---|---|---|---|---|
James et al., 2017 [7] | Open label-phase III | 1917 | Abiraterone prednisone 5 mg qd ADT | ADT alone | 4 |
Fizazi et al., 2017 [13] | Double-blind phase III | 1199 | Abiraterone Prednisone 5 mg qd ADT | ADT + placebo | 5 |
Ryan et al., 2015 [9] | Double-blind phase III | 1088 | Abiraterone Prednisone 5 mg bid | Placebo Prednisone 5 mg bid | 5 |
Taplin et al., 2014 [14] | Open label phase II | 56 | Abiraterone Prednisone 5 mg qd ADT | ADT alone | 3 |
Fizazi et al., 2012 [6] | Double-blind phase III | 1185 | Abiraterone Prednisone 5 mg bid | Placebo Prednisone 5 mg bid | 5 |